Evidence for SARS-CoV-2 Delta and Omicron co-infections and recombination
Copyright © 2022 Elsevier Inc. All rights reserved..
BACKGROUND: Between November 2021 and February 2022, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta and Omicron variants co-circulated in the United States, allowing for co-infections and possible recombination events.
METHODS: We sequenced 29,719 positive samples during this period and analyzed the presence and fraction of reads supporting mutations specific to either the Delta or Omicron variant.
FINDINGS: We identified 18 co-infections, one of which displayed evidence of a low Delta-Omicron recombinant viral population. We also identified two independent cases of infection by a Delta-Omicron recombinant virus, where 100% of the viral RNA came from one clonal recombinant. In the three cases, the 5' end of the viral genome was from the Delta genome and the 3' end from Omicron, including the majority of the spike protein gene, though the breakpoints were different.
CONCLUSIONS: Delta-Omicron recombinant viruses were rare, and there is currently no evidence that Delta-Omicron recombinant viruses are more transmissible between hosts compared with the circulating Omicron lineages.
FUNDING: This research was supported by the NIH RADx initiative and by the Centers for Disease Control Contract 75D30121C12730 (Helix).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
Med (New York, N.Y.) - 3(2022), 12 vom: 09. Dez., Seite 848-859.e4 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bolze, Alexandre [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alternative allele fraction |
|---|
| Anmerkungen: |
Date Completed 16.12.2022 Date Revised 17.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.medj.2022.10.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348465157 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348465157 | ||
| 003 | DE-627 | ||
| 005 | 20231226040301.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.medj.2022.10.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1161.xml |
| 035 | |a (DE-627)NLM348465157 | ||
| 035 | |a (NLM)36332633 | ||
| 035 | |a (PII)S2666-6340(22)00449-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bolze, Alexandre |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evidence for SARS-CoV-2 Delta and Omicron co-infections and recombination |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2022 | ||
| 500 | |a Date Revised 17.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Between November 2021 and February 2022, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta and Omicron variants co-circulated in the United States, allowing for co-infections and possible recombination events | ||
| 520 | |a METHODS: We sequenced 29,719 positive samples during this period and analyzed the presence and fraction of reads supporting mutations specific to either the Delta or Omicron variant | ||
| 520 | |a FINDINGS: We identified 18 co-infections, one of which displayed evidence of a low Delta-Omicron recombinant viral population. We also identified two independent cases of infection by a Delta-Omicron recombinant virus, where 100% of the viral RNA came from one clonal recombinant. In the three cases, the 5' end of the viral genome was from the Delta genome and the 3' end from Omicron, including the majority of the spike protein gene, though the breakpoints were different | ||
| 520 | |a CONCLUSIONS: Delta-Omicron recombinant viruses were rare, and there is currently no evidence that Delta-Omicron recombinant viruses are more transmissible between hosts compared with the circulating Omicron lineages | ||
| 520 | |a FUNDING: This research was supported by the NIH RADx initiative and by the Centers for Disease Control Contract 75D30121C12730 (Helix) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BA.1 | |
| 650 | 4 | |a Delta | |
| 650 | 4 | |a Omicron | |
| 650 | 4 | |a RNA virus | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Translation to patients | |
| 650 | 4 | |a alternative allele fraction | |
| 650 | 4 | |a breakpoint | |
| 650 | 4 | |a co-infection | |
| 650 | 4 | |a recombination | |
| 650 | 4 | |a sequencing | |
| 700 | 1 | |a Basler, Tracy |e verfasserin |4 aut | |
| 700 | 1 | |a White, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Dei Rossi, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Wyman, Dana |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Hang |e verfasserin |4 aut | |
| 700 | 1 | |a Roychoudhury, Pavitra |e verfasserin |4 aut | |
| 700 | 1 | |a Greninger, Alexander L |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashibara, Kathleen |e verfasserin |4 aut | |
| 700 | 1 | |a Beatty, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Seema |e verfasserin |4 aut | |
| 700 | 1 | |a Stous, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a McCrone, John T |e verfasserin |4 aut | |
| 700 | 1 | |a Kil, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Cassens, Tyler |e verfasserin |4 aut | |
| 700 | 1 | |a Tsan, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Jason |e verfasserin |4 aut | |
| 700 | 1 | |a Ramirez, Jimmy |e verfasserin |4 aut | |
| 700 | 1 | |a Carter, Scotty |e verfasserin |4 aut | |
| 700 | 1 | |a Cirulli, Elizabeth T |e verfasserin |4 aut | |
| 700 | 1 | |a Schiabor Barrett, Kelly |e verfasserin |4 aut | |
| 700 | 1 | |a Washington, Nicole L |e verfasserin |4 aut | |
| 700 | 1 | |a Belda-Ferre, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobs, Sharoni |e verfasserin |4 aut | |
| 700 | 1 | |a Sandoval, Efren |e verfasserin |4 aut | |
| 700 | 1 | |a Becker, David |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, James T |e verfasserin |4 aut | |
| 700 | 1 | |a Isaksson, Magnus |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, William |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Shishi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Med (New York, N.Y.) |d 2020 |g 3(2022), 12 vom: 09. Dez., Seite 848-859.e4 |w (DE-627)NLM314117954 |x 2666-6340 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2022 |g number:12 |g day:09 |g month:12 |g pages:848-859.e4 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.medj.2022.10.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2022 |e 12 |b 09 |c 12 |h 848-859.e4 | ||